EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study

Denis Arikci, Friederike Holze iD, Lorenz Mueller iD, Patrick Vizeli iD, Deborah Rudin iD, Dino Luethi iD, Cedric M Hysek, Matthias E Liechti iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3726 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Denis Arikci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Lysergic Acid Diethylamide, Tartrates, Hallucinogens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University Hospital Basel, Mind Medicine, Inc, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent. Additionally, LSD's absolute oral bioavailability is unknown. Therefore, we tested the bioequivalence of different oral LSD base and tartrate formulations and defined LSD's absolute oral bioavailability at a dose of ~80 μg freebase equivalent. We used a randomized, double‐blind, placebo‐controlled, five‐period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos. We assessed pharmacokinetic parameters and acute subjective, autonomic, and adverse effects up to 24 hours. All oral formulations were bioequivalent, with the ethanolic base solution as a reference. The area under the concentration–time curve from zero to infinity and maximum plasma concentration were within a 90% confidence interval of 80–125%. The absolute bioavailability of oral LSD was 80% and similar for all tested formulations. Overall, the oral formulations showed comparable pharmacokinetic and pharmacodynamic parameters. Intravenous LSD administration produced higher “any drug effect,” “good drug effect,” and “ego dissolution” compared with oral LSD tartrate, more “anxiety” compared with all oral formulations, and more “nausea” and “bad drug effect” compared with oral LSD base and tartrate. In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lysergic Acid DiethylamideTartratesHallucinogensHumansCross-Over StudiesDouble-Blind MethodMaleAdultBiological AvailabilityAdministration, OralYoung AdultTherapeutic EquivalencyFemaleHealthy VolunteersArea Under CurveMiddle AgedAdministration, Intravenous

Substanzen

Lysergic Acid DiethylamideTartratesHallucinogens

Autor:innen und Institutionen

  • Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
  • Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Apotheke Dr. Hysek AG, Biel/Bienne, Switzerland.

ORCID-Profile: Friederike Holze, Lorenz Mueller, Patrick Vizeli, Deborah Rudin, Dino Luethi, Matthias E Liechti

Förderung

  • University Hospital Basel
  • Mind Medicine, Inc
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Universitätsspital Basel

Zitieren

APA

Arikci, D., Holze, F., Mueller, L., Vizeli, P., Rudin, D., Luethi, D., Hysek, C. M., & Liechti, M. E. (2025). Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3726

Vancouver

Arikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, et al. Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3726

BibTeX
@article{Arikci2025,
  author = {Arikci, Denis and Holze, Friederike and Mueller, Lorenz and Vizeli, Patrick and Rudin, Deborah and Luethi, Dino and Hysek, Cedric M and Liechti, Matthias E},
  title = {Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3726}
}
Kostenlos starten →